ブランドジェネリック市場：製品タイプ、薬剤タイプ、投与経路、適応症、流通チャネル別-2025-2030年の世界予測

ブランドジェネリック市場は、2023年に4,323億米ドルと評価され、2024年には4,942億9,000万米ドルに達すると予測され、CAGR 14.66%で成長し、2030年には1兆1,264億3,000万米ドルに達すると予測されています。

ブランドジェネリックは、製薬会社がブランド名を付けて販売する特許切れ医薬品を指し、ブランドロイヤリティの優位性を保ちながら、ジェネリック医薬品に代わる費用対効果の高い選択肢を提供します。その必要性は、手頃な価格と品質保証のバランスにあり、ヘルスケアコストが重要視される地域では不可欠なものとなっています。これらの医薬品は通常、複数の治療領域に適用され、慢性疾患から急性期治療まで幅広い治療に使用され、エンドユーザーはヘルスケアプロバイダー、病院、個人消費者など多岐にわたる。ブランドジェネリックの成長を促進する主な要因としては、慢性疾患の有病率の増加、手頃な価格の医薬品に対する需要の高まり、医療へのアクセスが制限されているもの重要性が増している新興市場での拡大などが挙げられます。最新のビジネスチャンスは、デジタル・マーケティング・チャネルを活用してブランドの存在感を高めること、新興市場での戦略的提携や買収に注力して流通網を広げることにあります。しかし、市場は厳しい規制環境、熾烈な価格競争、知的財産権に関する懸念などの課題に直面しており、これらは成長の妨げとなる可能性があります。また、市場アクセスや薬価に影響を与えかねないヘルスケア政策の絶え間ない進化にも限界があります。イノベーションは、バイオシミラーや個別化医療の開発を模索することで、ブランドは患者に特化したソリューションに注力することで差別化を図ることができます。さらに、先進的なドラッグデリバリー・メカニズムやデジタル・ヘルス・モニタリング・ツールに投資することで、ブランドは競争力を高めることができると思われます。ブランドジェネリック市場の競争は中程度であり、多数の世界企業や地域企業が市場シェアの獲得にしのぎを削っているため、継続的なイノベーションと顧客志向の戦略が必要となります。持続的成長のためには、研究開発への投資、サプライチェーン効率の最適化、新興市場参入戦略の優先順位付けを行うとともに、規制の変化に積極的に対応することが推奨されます。限界を乗り越えながら市場機会を捉えるには、経営の俊敏性と強力なブランド差別化の両方が不可欠です。

市場力学：急速に進化するブランドジェネリック市場の主要市場インサイトを公開

ブランドジェネリック市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ジェネリック医薬品の使用を必要とする慢性疾患の流行
  • ブロックバスター医薬品の特許切れの増加と費用対効果の高い代替品へのニーズ
• 市場抑制要因
  • ブランドジェネリック医薬品の品質ばらつきに関する懸念
• 市場機会
  • 新たな生物学的同等性試験と市場参入企業によるブランドジェネリック事業拡大への取り組み
• 市場の課題
  • 訴訟問題、新薬の価格下落に関する問題

ポーターの5つの力：ブランドジェネリック市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ブランドジェネリック市場における外部からの影響の把握

外部マクロ環境要因は、ブランドジェネリック市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ブランドジェネリック市場における競合情勢の把握

ブランドジェネリック市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスブランドジェネリック市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ブランドジェネリック市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ジェネリック医薬品の使用を必要とする慢性疾患の蔓延
    • ブロックバスター医薬品の特許切れの増加と費用対効果の高い代替品の必要性
  • 抑制要因
    • ブランドジェネリック医薬品の品質のばらつきに関する懸念
  • 機会
    • 新たな生物学的同等性研究と市場プレーヤーによるブランドジェネリック事業拡大への取り組み
  • 課題
    • 訴訟問題および先発医薬品の価格下落に関する問題
• 市場セグメンテーション分析
  • 製品：付加価値のあるブランドジェネリックの大幅な採用により、追加の利点がもたらされる
  • 薬剤の種類：高血圧の治療に降圧剤を多く使用
  • 投与経路：作用持続時間が長いため経口投与が広く採用されている
  • 適応症：消化器疾患および神経疾患におけるブランドジェネリックの利用が急増
  • 配信チャネル：ブランドジェネリックのオンライン配信チャネルの進化
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ブランドジェネリック市場：製品別

• 商品名ジェネリック医薬品
• 付加価値

第7章 ブランドジェネリック市場薬の種類別

• アルキル化剤
• 抗うつ薬
• 抗てんかん薬
• 降圧剤
• 抗精神病薬
• 代謝拮抗物質
• ホルモン
• 脂質低下薬

第8章 ブランドジェネリック市場：投与経路別

• オーラル
• 非経口
• 話題

第9章 ブランドジェネリック市場適応症別

• 急性および慢性疼痛
• 心血管疾患
• 皮膚疾患
• 消化器疾患
• 神経疾患
• 腫瘍学

第10章 ブランドジェネリック市場：流通チャネル別

• オフライン
  • 病院薬局
  • 小売薬局
• オンライン

第11章 南北アメリカのブランドジェネリック市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のブランドジェネリック市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのブランドジェネリック市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • VyvanseジェネリックがFDAに承認
  • 製薬連盟とジェネリック医薬品協会がジェネリック医薬品の価格設定協定を更新
  • アムニール社、ザイレム（オキシバトナトリウム）の認可ジェネリックを発売、複合ジェネリック5品目のFDA承認を取得
  • アジャンタファーマは成長著しいアジア、アフリカ地域での事業拡大を目指す
  • ドクター・レディーズが国内市場でジェネリック医薬品事業に参入
  • サンファーマ、ファイザーの大ヒット抗がん剤のジェネリック版を発売
  • ゼンティバ、ティロメッド・スペインからの主要製品買収を完了
  • シプラ社、便秘解消のための無糖経口乳剤下剤「イージーラックス L」を発売
  • プロキャップス・グループ、アドベント・インターナショナルからグルポ・ソマールを買収

企業一覧

• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Viatris Inc.
• Sandoz International GmbH by Novartis AG
• Bausch Health Companies Inc.
• GlaxoSmithKline PLC
• Amneal Pharmaceuticals LLC
• Eris Lifesciences Limited
• Alkem Laboratories Ltd.
• Cipla Limited
• Zentiva Group, a.s.
• Nichi-Iko Pharmaceutical Co., Ltd.
• Endo International PLC
• Aurobindo Pharma Limited
• AstraZeneca PLC
• Eva Pharma
• Hetero Drugs Limited
• Abbott Laboratories
• Glenmark Pharmaceuticals Limited
• Fresenius Kabi AG
• Pfizer Inc.
• Aspen Pharmacare Holdings Limited
• Sun Pharmaceutical Industries Ltd.
• Ajanta Pharma Ltd.
• Apotex Inc.
• Bristol-Myers Squibb Company
• Sanofi S.A.
• Micro Labs Limited
• Torrent Pharmaceuticals Ltd.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
• FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BRANDED GENERICS MARKET DYNAMICS
• TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 55. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 87. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 93. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 196. ITALY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 197. ITALY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 198. ITALY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 200. ITALY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. ITALY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 220. POLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 221. POLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 222. POLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 224. POLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. POLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 226. QATAR BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 227. QATAR BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 228. QATAR BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 230. QATAR BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 231. QATAR BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 286. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 287. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

The Branded Generics Market was valued at USD 432.30 billion in 2023, expected to reach USD 494.29 billion in 2024, and is projected to grow at a CAGR of 14.66%, to USD 1,126.43 billion by 2030.

Branded generics refer to off-patent drugs that are sold under a brand name by pharmaceutical companies, offering a cost-effective alternative to generic drugs while retaining brand loyalty advantages. Their necessity arises from the balance they offer between affordability and quality assurance, making them integral in regions where healthcare costs are critical. These drugs are typically applied across multiple therapeutic areas, used in treatments from chronic diseases to acute care, with end-users ranging from healthcare providers, hospitals, and individual consumers. Key factors driving the growth of branded generics include an increase in the prevalence of chronic diseases, rising demand for affordable medication, and expansion in emerging markets where healthcare access is limited yet increasingly crucial. Latest opportunities lie in leveraging digital marketing channels to enhance brand presence and focusing on strategic partnerships or acquisitions in emerging markets to widen distribution networks. However, the market faces challenges such as stringent regulatory environments, fierce price competition, and intellectual property concerns, which can hinder growth. Limitations also stem from the constant evolution of healthcare policies that can affect market access and drug pricing. Innovations could explore the development of biosimilars and personalized medicine as brands could differentiate by focusing on patient-specific solutions. Additionally, investing in advanced drug delivery mechanisms and digital health monitoring tools could provide brands a competitive edge. The nature of the branded generics market is moderately competitive, with numerous global and regional players striving for market share, necessitating continual innovation and customer-oriented strategies. For sustained growth, companies are recommended to invest in R&D, optimize supply chain efficiency, and prioritize emerging market entry strategies while adapting to regulatory changes proactively. The need for both operational agility and strong brand differentiation is paramount in capturing market opportunities while navigating the limitations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Branded Generics Market

The Branded Generics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases necessitating the use of generic medications
  • Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
• Market Restraints
  • Concerns associated with quality variations in branded generic medications
• Market Opportunities
  • Novel bioequivalence studies and efforts by market players to expand branded generics business
• Market Challenges
  • Litigation issues and issues related to price erosion of innovator drugs

Porter's Five Forces: A Strategic Tool for Navigating the Branded Generics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Branded Generics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Branded Generics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Branded Generics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Branded Generics Market

A detailed market share analysis in the Branded Generics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Branded Generics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Branded Generics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories Ltd., Lupin Limited, Viatris Inc., Sandoz International GmbH by Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, Amneal Pharmaceuticals LLC, Eris Lifesciences Limited, Alkem Laboratories Ltd., Cipla Limited, Zentiva Group, a.s., Nichi-Iko Pharmaceutical Co., Ltd., Endo International PLC, Aurobindo Pharma Limited, AstraZeneca PLC, Eva Pharma, Hetero Drugs Limited, Abbott Laboratories, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Pfizer Inc., Aspen Pharmacare Holdings Limited, Sun Pharmaceutical Industries Ltd., Ajanta Pharma Ltd., Apotex Inc., Bristol-Myers Squibb Company, Sanofi S.A., Micro Labs Limited, Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Trade Named Generics and Value-Added.
• Based on Drug Type, market is studied across Alkylating Agents, Anti-depressants, Anti-epileptics, Anti-hypertensive, Anti-psychotics, Antimetabolites, Hormones, and Lipid Lowering Drugs.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on Indication, market is studied across Acute & Chronic Pain, Cardiovascular Diseases, Dermatological Diseases, Gastrointestinal Diseases, Neurological Diseases, and Oncology.
• Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
    • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with quality variations in branded generic medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
  • 5.1.4. Challenges
    • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
  • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
  • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
  • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
  • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Branded Generics Market, by Product

• 6.1. Introduction
• 6.2. Trade Named Generics
• 6.3. Value-Added

7. Branded Generics Market, by Drug Type

• 7.1. Introduction
• 7.2. Alkylating Agents
• 7.3. Anti-depressants
• 7.4. Anti-epileptics
• 7.5. Anti-hypertensive
• 7.6. Anti-psychotics
• 7.7. Antimetabolites
• 7.8. Hormones
• 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Topical

9. Branded Generics Market, by Indication

• 9.1. Introduction
• 9.2. Acute & Chronic Pain
• 9.3. Cardiovascular Diseases
• 9.4. Dermatological Diseases
• 9.5. Gastrointestinal Diseases
• 9.6. Neurological Diseases
• 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Offline
  • 10.2.1. Hospital Pharmacy
  • 10.2.2. Retail Pharmacy
• 10.3. Online

11. Americas Branded Generics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Branded Generics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Vyvanse Generics Approved by FDA
  • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
  • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
  • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
  • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
  • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
  • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
  • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
  • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

Companies Mentioned

• 1. Dr. Reddy's Laboratories Ltd.
• 2. Lupin Limited
• 3. Viatris Inc.
• 4. Sandoz International GmbH by Novartis AG
• 5. Bausch Health Companies Inc.
• 6. GlaxoSmithKline PLC
• 7. Amneal Pharmaceuticals LLC
• 8. Eris Lifesciences Limited
• 9. Alkem Laboratories Ltd.
• 10. Cipla Limited
• 11. Zentiva Group, a.s.
• 12. Nichi-Iko Pharmaceutical Co., Ltd.
• 13. Endo International PLC
• 14. Aurobindo Pharma Limited
• 15. AstraZeneca PLC
• 16. Eva Pharma
• 17. Hetero Drugs Limited
• 18. Abbott Laboratories
• 19. Glenmark Pharmaceuticals Limited
• 20. Fresenius Kabi AG
• 21. Pfizer Inc.
• 22. Aspen Pharmacare Holdings Limited
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Ajanta Pharma Ltd.
• 25. Apotex Inc.
• 26. Bristol-Myers Squibb Company
• 27. Sanofi S.A.
• 28. Micro Labs Limited
• 29. Torrent Pharmaceuticals Ltd.
• 30. Teva Pharmaceutical Industries Ltd.